Early benefit assessment: Detailed analysis of all G-BA resolutions

The AMNOG monitor provides current, well-founded analyses of all early benefit assessments and an overview of the negotiated reimbursement prices in Germany. It is an indispensable tool for HTA, market access and pricing managers.
 

 

 

List of all G-BA Resolutions

The AMNOG monitor includes detailed analyses of every single benefit assessment since 2011. more >>

Interactive Analysis

Our comprehensive online analysis tool helps answer your individual questions. more >>

Intelligent search

Search for answers in all G-BA resolutions, justifications, IQWiG assessments and much more >>

Reimbursement Price Trends

See the development of manufacturers' prices and yearly therapy costs of all products with negotiated reimbursement prices. more >>

"Interactive analysis" step by step

A quick tour through the AMNOG Monitor's powerful analysis tool. more >>

"Detailed analysis" step by step

A tour through the structure of our quantitative and qualitative analyses of each G-BA resolution. more >>

Resolutions January 2026

Dear readers of AMNOG Monitor,

The European Council and the European Parliament have agreed on new rules for a fairer and more competitive EU pharmaceutical sector. This is intended to represent an important breakthrough for health protection, security of supply and innovation capacity in Europe in a difficult geopolitical environment.

A Pharmaceutical Strategy for Europe - Public Health

In December, there were nine new decisions on early benefit assessment (Fig. A) and 8 new procedures were initiated (Fig. B). The price changes are shown in Fig. C and the current EU HTA procedures are shown at the link below.

In 2025, only 12 EU HTA procedures for new active substances in oncology and ATMP were launched instead of the expected 25, two of which were launched last month: Ensartinib for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) and zopapogene imadenovec for the treatment of respiratory papillomatosis in adults. The first Joint Clinical Assessment (JCA) is expected in the second quarter of 2026.
Ongoing EU HTA procedures (Excel)

This year, we have completely re-programmed the AMNOG Monitor with many new features:

  • Intelligent search is now 5-10 times faster (01.01.2026) and Excel downloads are also faster (01.01.2026)
  • Daily tracking of EMA approval status, including positive opinions (01.01.2026)
  • The EU HTA is an integral part of the new AMNOG Monitor (01.01.2026)
  • New parameters such as patient numbers in clinical trials >5%, confidential reimbursement amount
  • Effect measures of patient-relevant endpoints with confidence intervals and p-values (from 1 April 2026)
  • MFN tracking from 1 July 2026
  • Price tracking of all ZVTs from 1 July 2026

With the re-programming, we can process around 100 times the amount of data at the same speed. All our servers are now located in Germany or within the EU, and numerous cyber security measures have been implemented.

Your access data will remain unchanged. We will provide you with details in January 2026 and in the training courses, which we strongly recommend in 2026.

New reimbursement prices of AMNOG products are available here.
EMA Positive Opinions for new drugs are shown here.

We thank you for your trust and wish you a relaxing New Year's holiday.
We look forward to continuing to work with you.

Dr. Johannes Hankowitz
München, 23 December 2025